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Abstract 13 
Between March 2011 and February 2012 83 E. coli strains were isolated from mastitis milk 14 
samples from 83 different animals (67 farms) and tested for their sensitivity to various 15 
antibiotics by means of disk diffusion method and genotyped by determination of the 16 
phylogenetic groups as well as by pulsed field gel electrophoresis (PFGE). The antibiotics 17 
were chosen on the basis of their licenses for intramammary application in Switzerland. As 18 
many as 16.9 % of the isolates were resistant to one or more antimicrobial agents. 19 
Amoxicillin-clavulanic acid, gentamicin and third generation cephalosporins proved effective 20 
against the majority of these strains. Nevertheless, one blaCTX-M-14 harbouring extended-21 
spectrum-beta-lactamase producing strain was found.  Genetic analysis grouped most of the 22 
strains (87%) into phylogenetic groups A and B1. PFGE genotyping demonstrated that E. coli 23 
from cows with mastitis even from the same farm were genotypically very diverse. 24 
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Resistenzprofile und genetische Vielfalt von Escherichia coli Stämmen isoliert aus 30 
akuten bovine Mastitiden 31 
Zwischen März 2011 und Februar 2012 wurden 83 E. coli Stämme von 83 verschiedenen 32 
Kühen aus 67 Betrieben gesammelt und auf ihre Empfindlichkeit gegenüber verschiedenen 33 
Antibiotika getestet. Die Antibiotika wurden aufgrund der Zulassung für eine intramammäre 34 
Applikation in der Schweiz ausgesucht und die Empfindlichkeitstestung mittels 35 
Agardiffusions-Methode durchgeführt. Zudem wurden alle Stämme hinsichtlich ihrer 36 
Zugehörigkeit zu den phylogenetischen Gruppen wie auch mittels Pulsfeldgelelektrophorese 37 
(PFGE) genotypisiert. 16.9% aller Stämme zeigten Resistenzen gegenüber einem oder 38 
mehreren Antibiotika. Amoxicillin-Clavulansäure, Gentamicin und Cephalosporine der 39 
dritten Generation erwiesen sind als wirksam gegen die Mehrheit der E. coli Stämme. Jedoch 40 
wurde ein extended-Spectrum-beta-Lactamase Bildner, welcher das blaCTX-M-14-Gen trägt, 41 
gefunden. Die genetische Analyse gruppierte das Gros der Stämme (87%) in die 42 
phylogentischen Guppen A und B1. Die weitere Genotypisierung mittels PFGE zeigte eine 43 
grosse Diversität unter den E. coli Stämmen, auch wenn diese vom selben Betrieb stammten. 44 
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Introduction 48 
Mastitis remains a major challenge to the worldwide dairy industry. For Switzerland, the 49 
average annual cost due to clinical mastitis has been estimated to be about SF 300.- per cow 50 
(Rüsch, 1995). Escherichia coli is the most common Gram-negative bacterium causing acute 51 
mastitis in cows worldwide (Hogan and Smith, 2003, Ericsson Unnerstad et al., 2009). E. coli 52 
induced mastitis is characterized as a relatively short-term disease process and induces a 53 
distinct acute phase response. 54 
Antimicrobial treatment of an acute clinical mastitis has to start before the results of 55 
antimicrobial susceptibility testing are available because of the very often peracute course of 56 
the disease. Knowledge on current resistance patterns guides this "empiric" treatment and will 57 
enable a more accurate use of antibiotics. The latest published data on resistance profiles of E. 58 
coli causing mastitis in cows in Switzerland are about 10 years old (Stephan and Rüsch, 1997; 59 
Corti et al., 2003). In the meantime extended spectrum β-lactamases (ESBL) producing E. 60 
coli isolated from milk of cows with clinical mastitis were described (Locatelli et al., 2009). 61 
And recently, a CMY-2 β-lactamase producing E. coli (plasmid-mediated AmpC-producing 62 
E. coli) isolated from a cow with recurrent mastitis, was found in Switzerland (Endimiani et 63 
al., 2012). Therefore, from a clinical perspective, current data about resistances profiles of E. 64 
coli are required.  65 
The E. coli species encompasses both pathogenic and non-pathogenic strains. Pathogenic 66 
strains cause a variety of enteric and extraintestinal infections in humans and animals, mostly 67 
in a host- or organ-specific way. Nevertheless, with regard to bovine mastitis, an E. coli 68 
pathogenic subset has not been identified yet. Bovine mastitis E. coli do not belong to specific 69 
antigen O serogroups (Wenz et al., 2006) and are not biochemically different from fecal E. 70 
coli  (Nemeth et al., 1994). Because of this apparent lack of specific features, it has been 71 
largely accepted that there is no strain specificity in E. coli bovine mastitis and that various E. 72 
coli strains found in the environment bear the same potential to cause the disease (Burvenich 73 
et al., 2003, Fernandes et al. 2011). The aim of this study was to retrieve current data on 74 
resistance profiles of E. coli strains form bovine mastitis milk samples as well as on the 75 
degree of genetic variability among isolates in Switzerland.  76 
  77 
 78 
   79 
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Material and Methods 81 
 4 
 82 
Strains 83 
A total of 83 E. coli strains from acute clinical cases of bovine mastitis were isolated from 83 84 
different animals (67 different farms distributed in the cantons of Zurich, Graubünden, 85 
Thurgau, Aargau, St. Gallen, Uri and Zug). Not more than two cows per farm were included. 86 
The isolates were collected between March 2011 and February 2012. Milk samples were 87 
taken during farm calls by the attending veterinarian from the affected quarter of each cow in 88 
an aseptical manner.  89 
Using a sterile loop, the samples were streaked onto sheep blood agar base (Beckton 90 
Dickinson AG, Allschwil, Switzerland), supplemented with 5 % sheep blood (Oxoid, Pratteln, 91 
Switzerland) as well as onto BROLACIN-Agar (VWR International AG, Dietikon, 92 
Switzerland) and incubated at 37 °C overnight. The E. coli strains were confirmed by colony 93 
morphology, Gram stain, and biochemical tests such as acid production from mannit, ONPG 94 
test, tests for urease, indol and H2S production and the lysindecarboxylase test. The strains 95 
were stored at -80°C. 96 
 97 
Susceptibility Testing 98 
The strains were subjected to antimicrobial susceptibility testing using the standard disk 99 
diffusion test according to the protocols recommended by the Clinical and Laboratory 100 
Standards Institute (2008). The antimicrobial agents tested as well as the corresponding 101 
interpretative criteria are summarized in Table 1. Bacteria were grown 4 – 5 h in BHI (Brain 102 
Heart Infusion, Oxoid, Pratteln, Switzerland) and diluted to 0.5 Mac Farland turbidity by 103 
comparison with a standard. Thereafter, bacterial suspensions were swabbed uniformly across 104 
a Müller-Hinton-Agar (Oxoid, Pratteln, Switzerland) plate and the filter-paper disks 105 
impregnated with the antimicrobial were placed on the surface of the agar using a dispenser. 106 
The disks were provided from Beckton Dickinson AG, Allschwil, Switzerland, except 107 
Ceftiofur, which was provided from Oxoid, Pratteln, Switzerland. Plates were incubated at 35 108 
°C for 18 h and the zone of inhibition (in mm) was assessed and measured using a calliper. 109 
Interpretive criteria according to the performance standards for antimicrobial disk and dilution 110 
susceptibility tests for bacteria isolated from animals (Clinical and Laboratory Standards 111 
Institute, 2008) were used. Accuracy of the test system was monitored by including the 112 
reference strain E. coli ATCC 25922. 113 
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Additionally the strains were cultured on Brilliance ESBL agar (Oxoid, Pratteln, Switzerland) 114 
and incubated for 24h at 37°C. Strains, which were able to produce blue colonies, were 115 
confirmed as ESBL producers on Muller-Hinton agar plates using E-Test-ESBL strips 116 
containing cefotaxime, cefepime or ceftazidime each alone and in combination with 117 
clavulanic acid (bioMérieux, Marcy l’Etoile, France) according to the manufacturer’s 118 
recommendations. 119 
 120 
Identification and sequencing of blaESBL genes 121 
Bacterial strains confirmed for producing ESBLs were further analysed by PCR and by 122 
sequencing the whole open reading frames (ORF) of bla genes. DNA was extracted by a 123 
standard heat lysis protocol. Thereafter, specific primer sets were used to search for β-124 
lactamase-encoding genes belonging to blaTEM, blaSHV and blaCTX-M families (Geser et al., 125 
2011; Geser et al. 2012). Resulting amplicons were purified using the PCR Purification Kit 126 
(QIAGEN, Courtaboeuf, France) according to the manufacturer’s recommendations. Custom-127 
sequencing was performed by Microsynth (Balgach, Switzerland) and the nucleotide and 128 
protein sequences were analyzed with Codon Code Aligner V. 3.7.1.1. For database searches 129 
the BLASTN program of NCBI (http://www.ncbi.nlm.nih.gov/blast/) was used. 130 
 131 
Determination of the E. coli phylogenetic groups 132 
Phylogenetic analyses have shown that E. coli strains fall into four main phylogenetic groups 133 
(A, B1, B2, D). All isolates in the collection were assigned to phylogenetic groups, in which 134 
group A/B1 typically contained commensal isolates and group B2/D isolates were associated 135 
with virulence, using a triplex PCR protocol (Clermont et al., 2000) after DNA extraction by a 136 
standard heat lysis protocol.  137 
 138 
PFGE 139 
Genetic variability of isolates was determined by macrorestricion analysis and pulsed field gel 140 
electrophoresis (PFGE) according to the PulseNet standardized protocol for the subtyping of 141 
E. coli O157, Salmonella, Shigella (Ribot et al., 2006). After electrophoresis the gels were 142 
ethidium bromide stained and the banding pattern was photographed under (UV) illumination 143 
and a digital image (that was converted to TIFF format) of the pattern was acquired using the 144 
GelDoc system (Bio-Rad). The TIFF images were analysed using the BioNumerics software 145 
GelCompare (Applied Maths, Sint-Martens-Latem, Belgium) and Dice coefficient and 146 
 6 
UPGMA was employed to generate dendrograms. Analysis parameters were set to 2 % for 147 
both optimization and tolerance values respectively. 148 
 149 
 150 
Results and Discussion 151 
 152 
Susceptibility Testing 153 
Prevalence data for resistances in view of the antibiotics tested are summarized in Table 1. In 154 
total, 16.9% (n=14) of the strains showed resistance to one or more antimicrobial agent: 2.4% 155 
(n=2) of all E. coli strains were resistant against gentamicin, 10.8% (n=9) were resistant 156 
against kanamycin, 15.7% (n=13) against ampicillin, 3.6% (n=3) against cephalothin and 157 
1.2% (n=1) against ceftiofur. No resistant strains were found for the combination amoxicillin-158 
clavulanic acid. Nine strains (10.8%) were resistant against more than one class of antibiotics, 159 
the most frequent ones showed resistance against kanamycin and ampicillin (7.2%, n=6). One 160 
strain (1.2%) showed resistance against kanamycin, ampicillin and cephalothin and another 161 
strain (1.2%) showed resistance against gentamicin, kanamycin and ampicillin. In addition we 162 
found one ESBL-producer, harbouring blaCTX-M-14, which was also resistant against the 163 
aminoglycosides kanamycin and gentamicin. The distributions of the inhibition zones of all 164 
strains are shown in Figure 1. 165 
A comparison of the results from this study with previous studies in Switzerland (Stephan and 166 
Rüsch, 1997, Corti et al., 2003) revealed no global changes in the resistance situation during 167 
the last 15 years. However, concerning cephalothin, 22 strains fell into the interpretative 168 
category "intermediate". This might indicate a shift of the population towards resistance and 169 
will need to be observed over the next years. By comparing the results of this study with 170 
recently published data from European countries (Hendriksen et al., 2008; Botrel et al., 2010) 171 
no obvious differences in view of resistance prevalence were evident.  172 
 173 
Phylogenetic groups  174 
Most of the isolates investigated could be assigned to phylogenetic groups A and B1, with 175 
29/83 (34.9%) assigned to group A and 43/83 (51.8%) assigned to group B1. Eleven isolates 176 
(13.3%) were assigned to the group D and none to phylogenetic group B2. With regard to 177 
virulence, phylogenetic groups B2 and D are considered to be more likely to carry 178 
pathogenicity-associated genes, while groups A and B1 are classified commensal strains 179 
(Clermont et al., 2000). In our study, most of the isolates belonged to groups A and B1. In this 180 
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context, it is worth mentioning, that this was in agreement with findings from a survey 181 
showing that E. coli isolates, shed by healthy cattle predominantly belonged to lineages A and 182 
B1 (Houser et al., 2008). However, it cannot be excluded that such strains may harbour some 183 
factors which may favour e.g. colonization of the udder.  184 
 185 
Genotyping 186 
The genetic variability was high among the 83 E. coli mastitis isolates from the 67 farms, and 187 
most of the strains were clonally not related based on a cut off value of 95% (Fig. 2). Even 188 
isolates from multiple cows from the same farm displayed diverse PFGE patterns. Only three 189 
PFGE patterns (two strains each were indistinguishable) were found in different farms (Fig. 190 
2). Our data confirm the results of Wenz et al. (2006), who also found a high heterogeneity 191 
among E. coli strains isolated from cows with mastitis. The high genetic heterogeneity among 192 
the strains underlines that, in contrast to S. aureus (Stutz et al., 2011), no specific E. coli 193 
clones are mainly responsible for the E. coli mastitis situation.  194 
This fact further highlights, that besides the use of antibiotics, the strategy for treatment of 195 
mastitis should be flanked by preventive measures. These comprise a number of approaches 196 
such as maintenance of a clean, dry, comfortable environment; proper milking procedures; 197 
proper maintenance and use of milking equipment; appropriate management of clinical 198 
mastitis during lactation; effective dry cow management; maintenance of biosecurity for 199 
contagious pathogens and culling of chronically infected cows as well as regular monitoring 200 
of udder health status. 201 
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 Table 1: Antimicrobial agents used in this study, interpretative criteria1 and prevalence of 275 
resistances (n=83)   276 
 277 
 278 
1according to M31-A3: Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for 279 
Bacteria Isolated From Animals; Approved Standard-Third Edition; CLSI, Wayne, USA 2008.  280 
 281 
 282 
 283 
  284 
285 
  resistant susceptible resistant strains (%) 
Antimicrobial agents  (inhibition zone 
diameters in mm) 
 
Gentamicin (GM) 10µg ≤12 ≥15 2.4 
Kanamycin (K) 30µg ≤13 ≥18 10.8 
Ampicillin (AM) 10µg  ≤13 ≥17 15.7 
Amoxicillin-clavulanic acid 
(AC) 
20/10µg 
≤13 ≥18 0 
Cephalothin (CF) 30µg ≤14 ≥18 3.6 
Ceftiofur (CFT) 30µg ≤17 ≥21 1.2 
 12 
Figure 1: Distribution of inhibition zone diameters for the tested antimicrobial agents (GM: 286 
gentamicin; K: kanamycin; AM: ampicillin; AC: amoxicillin-clavulanic acid; CF: 287 
cephalothin; CFT: ceftiofur). 288 
 289 
 290 
Figure 2: Cluster analysis and dendrogram of PFGE pattern of 83 E. coli isolates from 291 
mastitis milk samples. The dendrogram was generated using BioNumerics software 292 
GelCompare and Dice coefficient and UPGMA. Analysis parameters were set to 2 % for both 293 
optimization and tolerance values respectively. For clonal relationship, the cut off value (see 294 
line) was set at 95%.  295 
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 298 
